Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

64Cu-SAR-BBN Positron Emission Tomography: A Phase 2 Study of Participants With PSMA-negative Biochemical Recurrence of Prostate Cancer

NCT05407311 is registered in ClinicalTrials.gov with Clarity Pharmaceuticals Ltd as lead sponsor.

NCT NCT05407311
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05407311 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
64Cu-SAR-BBN Positron Emission Tomography: A Phase 2 Study of Participants With PSMA-negative Biochemical Recurrence of Prostate Cancer
Lead sponsor
Clarity Pharmaceuticals Ltd
Phase
Phase 2
Overall status
Completed
Start date
September 19, 2022
Completion date
May 13, 2024
Enrollment
53 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

biochemical recurrence of malignant neoplasm of prostate